Background: Bevacizumab (Bev) combined with platinum-based chemotherapy is a standard treatment for advanced non-squamous non-small-cell lung cancer (non-Sq NSCLC). Cisplatin þ pemetrexed (CisPem) is suggested as the most promising chemotherapy regimen combined with Bev. However, no study has been conducted to evaluate the efficacy and safety of CisPemBev compared with carboplatin þ paclitaxel þ bevacizumab (CarPacBev) for advanced non-Sq NSCLC. Methods: Treatment-naïve patients with advanced or recurrent EGFR/ALK-negative non-Sq NSCLC from 55 sites across Japan were randomly assigned in a 2:1 ratio to either CisPemBev ] þ Bev q3wk, followed by maintenance Bev q3wk until progression). The primary endpoint was progression-free survival (PFS) by central review. The secondary endpoints were overall survival (OS), overall response rate (ORR) and safety profile. The target numbers of patients and events were determined to be 210 and 170, respectively, to observe a point estimate of HR for PFS (CisPemBev/CarPacBev) <0.83 with a high probability (80%) when the true HR was 0.72. The data were cutoff in July, 2017. OS data were updated for this presentation in April, 2018. Results: Between May 2014 and May 2016, 199 patients were randomly assigned to receive CisPemBev (N ¼ 132) or CarPacBev (N ¼ 67). In the primary analysis, PFS events occurred in 171 patients. The HR for PFS by central review (CisPemBev/ CarPacBev) was 0.825 (95% CI 0.600-1.134, median PFS, 7.6 vs 7.0 months), and the ORR was 57% for CisPemBev and 55% for CarPacBev. OS events occurred in 119 patients. The median survival follow-up duration was 28.3 months. The median OS was 23.4 months for CisPemBev and 21.6 months for CarPacBev (HR 0.845, 95% CI 0.583-1.242). Conclusions: PFS was prolonged with CisPemBev compared with CarPacBev. However, there was no difference in OS between two arms. CisPem is the most effective chemotherapy regimen combined with Bev for advanced non-Sq NSCLC. Legal entity responsible for the study: National Cancer Center Hospital East. 
Background: NSCLC is frequent in elderly patients (pts), however there is limited information on the treatment of this population. This study describes the first-line treatment with bevacizumab (bev) of NSCLC elderly pts in real life in France. Methods: AVANTAGE is a non-interventional, prospective, multicenter French study conducted in pts with advanced NSCLC starting first-line chemotherapy (CT) with bev. It includes 2 cohorts, pts aged 65-70 (C1), or 70 (C2) . Data were collected at inclusion and every 3 months subsequently for 18 months. The primary objective was to describe CT used with bev in first-line in routine clinical practice. Results: A total of 249 pts were eligible (277 included) in 68 centers: 108 (43%) in C1 & 141 (57%) in C2. They were predominantly men (75%), ECOG PS 0-1 (85%) PS 2 (15%), G8 questionnaire score >14 (35%), stage IV (96%), Charlson comorbidity index unadjusted 2 (63%), and brain metastases identified in 18% of pts overall, 20% of pts in C2. Platinum-based doublet CT and pemetrexed (pem) was the most used combination with bev in 186 (75%) pts overall: -81% of pts in C1 (62% cisplatin-pem and 18% carboplatin-pem) -70% of pts in C2 (26% cisplatin-pem and 44% carboplatin-pem). The initial dose of bev with CT was 7.5 mg/kg/3 weeks in 70% of pts. Overall, maintenance treatment was administered to 61% pts, including 53% with bev (24% in monotherapy and 29% with pem). Maintenance was 64% in C1and 62% in C2. Median PFS was 7.1 months, and median OS was 12.3 months (14.9 months in C1, 11.3 months in C2). Overall, 92% of pts presented at least 1 AE. Pts with grade 3 AEs related to bev were 12% in C1 and 24% in C2. In the safety population (260), 148 pts died during the study. 3 pts (all in C2) died due to SAEs related to treatment (intestinal perforation; febrile neutropenia/septic shock/ thrombocytopenia; unknown cause). Conclusions: AVANTAGE is the 1st prospective cohort conducted in routine clinical practice in France in elderly pts eligible for 1st-line CT with bev. The most frequently used treatment was the combination of platinum-pem doublet (75% of pts). Bev effectiveness as 1st line treatment in NSCLC was consistent with the efficacy observed in clinical trials in the elderly as was the safety profile. 1436P Randomized phase II study comparing cisplatin 1 pemetrexed 1 bevacizumab with carboplatin 1 paclitaxel 1 bevacizumab in treatment-naïve advanced non-squamous non-small cell lung cancer (CLEAR study) 
